A comparative study of nebivolol and (S) atenolol on blood pressure and heart rate on essential hypertensive patients

Indian Journal of Pharmacology

Volumn 42, Issue 6, 2010, Pages 401-405

  Sahana, G N ^a   Sarala, N ^a   Kumar, T N ^a   Lakshmaiah, V ^a  

^a SRI DEVARAJ URS MEDICAL COLLEGE   (India)

Author keywords

(S) atenolol; Essential hypertension; nebivolol

Indexed keywords

ATENOLOL; NEBIVOLOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFECT; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; ESSENTIAL HYPERTENSION; FAMILY HISTORY; FATIGUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; KIDNEY FUNCTION TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

EID: 78149366652     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.71918     Document Type: Article

References (25)

1. Murray CJ, Lopez AD. Evidence based health policy: Lessons from the Global Burden of Disease Study. Science 1996;274:740-3.
2. Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch Intern Med 1996;156:1926-35.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: JNC 7 report. JAMA 2003;289:2560-72.
4. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
5. Camm AJ. Cardiovascular diseases: Systemic hypertension. In: Parveen Kumar, Clark M, editors. Kumar and Clark Clinical Medicine. 5th ed. Edinburgh: W B Saunders; 2002. p. 818-27.
6. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: Clinical implication. Drugs 2002;62:265-84.
7. Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-45.
8. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503.
9. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: A review. Drugs 1999;57:633-51.
10. Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw Hill Publishing Division; 2006. p. 237-95.
11. McCoy RA, Clifton GD, Clementi WA, Smith MD, Garvey TQ, Wermeling DP, et al. Pharmacodynamics of racemic and S (-) Atenolol in humans. J Clin Pharmacol 1994;34:816-22.
12. th ed. Mumbai: The Association of Physicians of India; 2003. p. 452-61.
13. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Endothelial dysfunction in hypertension: Fact and fancy? J Cardiovasc Pharm 1998;32:S41-7.
14. Brush JE Jr, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal endotheliumdependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992;19:809-15.
15. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, Van Gorsel E, Heemskerk JW, et al. Nebivolol: A third generation beta blocker that augments vascular nitric oxide release: Endothelial beta (2)-adrenergic receptor mediated nitric oxide production. Circulation 2000;102:677-84.
16. Cominacini L, Fratta Pasini A, Garbin U, Nava C, Davoli A, Criscuoli M, et al. Nebivolol and its 4-keto derivative increases nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003;42:1838-44.
17. Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM. The vasodilator action of Nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999;48:460-3.
18. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: A novel mechanism for antihypertensive action. Circulation 2003;107:2747-52.
19. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frölich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000;5:377-9.
20. Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000;36:S401-3.
21. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005;23:589-96.
22. Boydak B, Nalbantgil S, Fici F, Nalbantgil I, Zoghi M, Ozerkan F, et al. A randomized comparison of the effects nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Invest 2005;25:409-16.
23. Stoschitzky K, Egginger G, Zernig G, Klein W, Lindner W. Stereoselective features of (R) and (S)-Atenolol: Clinical pharmacological, pharmacokinetic, and radio ligand binding studies. Chirality 1993; 5:15-9.
24. Stoschitzky K, Lindner W, Rath M, Leitner C, Uray G, Zernig G, et al. Stereoselective hemodynamic effects of (R)- and (S)-propranolol in man. Naunyn- Schmiedeberg's Arch Pharmacol 1989;339:474-8.
25. Leong Wai Fun, Malini S, Mamatha SR, Asma Parveen et al. Current Index of Medical Specialities Medimedia Health Private Limited. Bangalore: CMPMedica India Private Ltd. 2006. p. 116.